Bringing the fundamentals into focus…
Back to Puma Biotechnology, Inc.
How Puma Biotechnology, Inc. stacks up
PBYI · against 421 other Healthcare companies of similar size
Growth
18/ 100
Below the middle of the pack.
Ranked #305 of 422 · scores higher than 26% of peers
Bars: peers in each 10-point band of the growth score71 peers with a growth score of 10–19, including PBYI · Click a bar to see the companies
Why growth scores 18?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings per share growth, revenue growth and 3-year revenue growth, which are weaker than most Healthcare peers.
- slower growth in earnings per share: weaker than 89% of peers. Earnings per share growth: -46.2% vs peer median 9.8%
- slower revenue growth over the last year: weaker than 76% of peers. Revenue growth: -2.9% vs peer median 6.1%
- slower revenue growth over three years: weaker than 71% of peers. 3-year revenue growth: 0.2% vs peer median 5.8%
Metric by metric
Position: dot = PBYI, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | PBYI | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 435 reported | -2.9% | 2.9% | 34% | 33% | |
| Earnings per share growthHigher is better · 219 reported | -46.2% | 3.9% | 14% | 33% | |
| 3-year revenue growthHigher is better · 412 reported | 0.2% | 2.9% | 40% | 33% |
Ranking by growth score
Top 5 and the companies ranked around PBYI| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 464M USD | 100 | 53 | |
| 2 | 433M USD | 99 | 81 | |
| 2 | 885M USD | 99 | 33 | |
| 2 | 609M USD | 99 | 91 | |
| 5 | 3.9B HKD (≈$493M) | 98 | 66 | |
| 305 | 222M GBP (≈$288M) | 18 | 13 | |
| 305 | 471M USD | 18 | 21 | |
| 305 | 474M USD | 18 | 46 | |
| 305 | 471M NZD (≈$282M) | 18 | 23 | |
| 305 | 528M USD | 18 | 58 | |
| 315 | 1.9B CNY (≈$270M) | 17 | 17 | |
| 315 | 7.1B CNY (≈$989M) | 17 | 38 | |
| 315 | 2.3B CNY (≈$323M) | 17 | 40 | |
| 315 | 1.9B CNY (≈$264M) | 17 | 27 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score